Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.

Disterer P, Al-Shawi R, Ellmerich S, Waddington SN, Owen JS, Simons JP, Khoo B.

Mol Ther. 2013 Mar;21(3):602-9. doi: 10.1038/mt.2012.264. Epub 2013 Jan 15.

2.
3.
4.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Bell DA, Hooper AJ, Watts GF, Burnett JR.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28. Review.

5.

The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

Jensen HK.

Dan Med Bull. 2002 Nov;49(4):318-45. Review.

PMID:
12553167
6.

ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.

Fisher WR, Zech LA, Stacpoole PW.

Arterioscler Thromb. 1994 Apr;14(4):501-10. Review.

7.

Low-density lipoprotein apheresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

8.

Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.

Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ.

Atherosclerosis. 2002 May;162(1):33-43.

PMID:
11947895
9.

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M.

J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.

10.

A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet.

Powell-Braxton L, Véniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO.

Nat Med. 1998 Aug;4(8):934-8. Erratum in: Nat Med 1998 Oct;4(10):1200.

PMID:
9701246
11.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
12.
15.

In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.

Elias N, Patterson BW, Schonfeld G.

Arterioscler Thromb Vasc Biol. 2000 May;20(5):1309-15.

16.

Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.

Toth PP.

J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S6-10. doi: 10.1016/j.jacl.2013.02.004. Epub 2013 Mar 27.

19.

Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation.

Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagné C, Couture P.

J Lipid Res. 2004 May;45(5):866-72. Epub 2004 Feb 16.

20.

Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.

Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Aukrust P, Retterstøl K, Ose L, Halvorsen B, Holven KB.

J Clin Lipidol. 2013 Mar-Apr;7(2):109-16. doi: 10.1016/j.jacl.2012.08.001. Epub 2012 Aug 8.

PMID:
23415429
Items per page

Supplemental Content

Write to the Help Desk